TITLE

FDA AUTHORIZES ALFERON LDO STUDY FOR FLU PREVENTION

PUB. DATE
February 2011
SOURCE
Biotech Business;Feb2011, Vol. 24 Issue 2, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article announces the decision of the U.S. Food and Drug Administration (FDA) to lift the clinical hold it placed on the Phase II double-blind randomized trial of Alferon LDO oral interferon alfa-n3 from Hemispherx Biopharma Inc. for the prevention and treatment of influenza. A review of a November 12, 2010 issue was completed by the FDA. According to William A. Carter, chairman and chief executive officer (CEO), they are pleased to resolve the FDA issues and move into possible trials in the U.S. and other countries.
ACCESSION #
57671490

 

Related Articles

  • Hemispherx Down on Ampligen FDA Rejection.  // Bioworld Week;12/7/2009, Vol. 17 Issue 49, p4 

    The article informs that the U.S. Food & Drug Administration (FDA) has rejected the chronic fatigue drug Ampligen manufactured by Hemispherx Biopharma Inc. It discusses the impact of the FDA's decision on the company. The shares of Hemispherx declined by 41 percent. The FDA wanted to have more...

  • Clinic Roundup.  // BioWorld Today;6/22/2011, Vol. 22 Issue 120, p6 

    This section offers news briefs on clinical trials. A letter was received by CorMedix Inc. regarding a special protocol assessment from the U.S. Food and Drug Administration for a Phase III trial of CRMD001. A material transfer and research agreement was signed by Hemispherx Biopharma Inc. with...

  • Other News To Note.  // BioWorld Today;8/25/2010, Vol. 21 Issue 164, p3 

    This section offers news briefs in the pharmaceutical industry. The U.S. Food and Drug Administration (FDA) has given a fast-track program designation to the HEAT study of Thermodox from Celsion Corp. combined with radiofrequency ablation. All the pending securities class actions will be settled...

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • HEMISPHERX/ARMADA TO LAUNCH ALFERON N INJECTION.  // Biotech Business;Jun2007, Vol. 20 Issue 6, p1 

    The article reports on the agreement between Hemispherx Biopharma Inc. and Armada Health Care for the launch of their natural interferon, Alferon N Injection (r), into Armada's Specialty Pharmacy infrastructure. The drug was approved by the U.S. Food and Drug Administration (FDA) for human...

  • In Search for Deficit Busters, CBO Eyes Offshore Profits. Serebrov, Mari // BioWorld Today;1/22/2013, Vol. 24 Issue 14, p1 

    The article reports response made by Hemispherx Biopharma Inc. to the letter from the U.S. Food and Drug Administration (FDA) on negative advisory panel review of its Ampligen drug for chronic fatigue syndrome. It mentions the case Hempispherx Biopharma and 54-year-old man named Robert Miller...

  • Ampligen Patient Hunger Strike; Hemispherx Takes CRL Tailspin. Osborne, Randy // BioWorld Today;2/ 6/2013, Vol. 24 Issue 25, p1 

    The article reports response made by Hemispherx Biopharma Inc. to the letter from the U.S. Food and Drug Administration (FDA) on negative advisory panel review of its Ampligen drug for chronic fatigue syndrome. It mentions the case Hempispherx Biopharma and 54-year-old man named Robert Miller...

  • Hemispherx Files Ampligen NDA.  // Bioworld Week;10/15/2007, Vol. 15 Issue 42, p5 

    The article reports that Philadelphia-based Hemispherx Biopharma Inc. filed to the Food and Drug Authority (FDA) a new drug application for Ampligen in the treatment of chronic fatigue syndrome (CFS). According to Hemispherx, it included a massive regulatory package data, that goes back over a...

  • Ampligen Down, Probe Aims At Hemispherx Execs' Moves. Osborne, Randy // BioWorld Today;12/21/2012, Vol. 23 Issue 247, p1 

    The article reports on the decision by the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee to vote against the approval of Hemispherx Biopharma Inc.'s Toll-like receptor 3 modulator Ampligen. The decision is based on safety and efficacy data. Voting patient Alaine Perry...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics